Cymbalta Maker Opposes Allowing Victims to Combine Forces in Lawsuit

Tuesday, September 16, 2014

Last week, DrugNews reported that lawyers have filed lawsuits in 15 different states for victims of severe Cymbalta withdrawal side effects, and see the number of cases growing quickly.

In an attempt to streamline the growing litigation against Eli Lilly for the defective drug, and give thousands of patients a more efficient means of legal recourse, lawyers last month asked that cases be combined under one judge in a special federal court, instead of being spread around the country.

Lawyers representing Cymbalta patients overwhelmingly support the move, as it will create a Cymbalta MDL just for these cases and allow a quick determination of whether Eli Lilly covered up side effect occurrence rates and severity.

However, sources reported this week that the pharmaceutical giant opposes the creating of a special Cymbalta lawsuit court, arguing that cases are vastly different and that the publicity will lead to additional litigation.

Until recently, Cymbalta was Lilly’s top-selling med, earning billions of dollars each year. On the market since 2004, it is now prescribed for a variety of conditions, including depression, anxiety, fibromyalgia and pain.

Initially, maker Eli Lilly told patients that around 1% of users may experience side effects while trying to stop taking the medicine. However, reports now show the company hid data showing the occurrence rate of severe withdrawals could be over 50%.

Also, Lilly didn’t give patients a viable means of tapering off Cymbalta. Thousands so far have complained of symptoms ranging from headaches and irritability to strong electrical-like shocks to the brain.

Regardless of Eli Lilly’s resistance to litigation, lawyers expect the company will be liable for damages to its patients. They are currently helping anyone affected file lawsuits.

cymbalta
cymbalta
withdrawal

Other drugs and devices in the news:

Tuesday, April 14, 2020
Elmiron
Sudden Rise in Elmiron Eye Disease Cases Raises Questions

Elmiron is a mild blood-thinner drug that has been around since 1996 and is prescribed to treat bladder pain or inflammation, a condition called interstitial cystitis.

Monday, April 13, 2020
Asbestos Mesothelioma
Estimated $30 Billion Left Unclaimed in Asbestos Victim Funds

Since many of the companies that sold asbestos or used it in their products have long since gone out of business, people who are diagnosed with asbestos-related cancers often think it’s too late to file a lawsuit.

Get in touch with us.

Call, email or live chat with us today to see how we can help.

call DrugNews.net
Need a quick answer? Call us!
email DrugNews.net
Reach out to us by email.
live chat with DrugNews
We are here to help now